From a theoretical pharmacological standpoint, combining a peptide with putative lipolytic activity (AOD 9604) with a potent triple incretin receptor agonist (retatrutide) could potentially amplify metabolic effects but this is speculative and raises the possibility of compounding adverse effects with no safety data to guide dosing or monitoring
BPC-157 + TB-500 Blend is a combination of two synthetic peptides widely studied in preclinical research for their role in cellular response processes, tissue remodeling, angiogenesis, and regulation of the extracellular matrix
A significant portion of the vitamin is lost before it ever reaches the bloodstream
We do not have additional information about any anti-doping investigations, and defer any further questions on the matter to USADA.
We are just choosing which marketing to believe
If you have pernicious anemia or severe malabsorption: Hydroxocobalamin 1,000mcg IM injections monthly (after loading phase)
